462 related articles for article (PubMed ID: 28159192)
1. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
[TBL] [Abstract][Full Text] [Related]
5. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
[TBL] [Abstract][Full Text] [Related]
6. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
[TBL] [Abstract][Full Text] [Related]
8. Eftrenonacog Alfa: A Review in Haemophilia B.
Hoy SM
Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
[TBL] [Abstract][Full Text] [Related]
9. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
[TBL] [Abstract][Full Text] [Related]
11. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
[TBL] [Abstract][Full Text] [Related]
12. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
[TBL] [Abstract][Full Text] [Related]
13. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
[TBL] [Abstract][Full Text] [Related]
14. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
Kenet G; Chambost H; Male C; Lambert T; Halimeh S; Chernova T; Mancuso ME; Curtin J; Voigt C; Li Y; Jacobs I; Santagostino E;
Thromb Haemost; 2016 Sep; 116(4):659-68. PubMed ID: 27583313
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries.
Funding E; Lowe G; Poulsen LH; Shapiro S; Oldenburg J; Eriksson D; Falk A; Rich C
Adv Ther; 2023 Sep; 40(9):3770-3783. PubMed ID: 37351812
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
17. Eftrenonacog Alfa: A Review in Haemophilia B.
Lamb YN; Hoy SM
Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
[TBL] [Abstract][Full Text] [Related]
20. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
Nolan B; Klukowska A; Shapiro A; Rauch A; Recht M; Ragni M; Curtin J; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Fischer K; Liesner R
Blood Adv; 2021 Jul; 5(13):2732-2739. PubMed ID: 34242387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
